Alnylam Pharmaceuticals (ALNY) Short term Debt (2024 - 2025)
Alnylam Pharmaceuticals (ALNY) reported Short term Debt of $121.3 million for Q3 2025, little changed quarter-over-quarter from $120.8 million in Q2 2025.
Alnylam Pharmaceuticals (ALNY) Short term Debt (2024 - 2025) Analysis & Trends
Alnylam Pharmaceuticals has reported Short term Debt for 2 years, with the latest figure at $121.3 million in Q3 2025.
- For the quarter ending Q3 2025, Short term Debt changed N/A year-over-year to $121.3 million; the trailing twelve-month figure through Sep 2025 stood at $121.3 million (changed N/A YoY), and the FY2024 full-year result was $93.8 million, changed N/A from the prior year.
- Short term Debt for Q3 2025 stood at $121.3 million, roughly flat from $120.8 million in the prior quarter.
- The five-year high for Short term Debt was $121.3 million in Q3 2025, with the low at $93.8 million in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Alnylam Pharmaceuticals | 37.04 Bn | 34.03 Bn | 959.66 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 121.30 Mn |
| Jun 30, 2025 | 120.80 Mn |
| Mar 31, 2025 | 118.10 Mn |
| Dec 31, 2024 | 93.80 Mn |